274 related articles for article (PubMed ID: 19583963)
1. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
Titus SA; Beacham D; Shahane SA; Southall N; Xia M; Huang R; Hooten E; Zhao Y; Shou L; Austin CP; Zheng W
Anal Biochem; 2009 Nov; 394(1):30-8. PubMed ID: 19583963
[TBL] [Abstract][Full Text] [Related]
2. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
Huang XP; Mangano T; Hufeisen S; Setola V; Roth BL
Assay Drug Dev Technol; 2010 Dec; 8(6):727-42. PubMed ID: 21158687
[TBL] [Abstract][Full Text] [Related]
3. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
[TBL] [Abstract][Full Text] [Related]
4. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
5. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
[TBL] [Abstract][Full Text] [Related]
6. Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-à-go-go related gene potassium channels.
Zou B; Yu H; Babcock JJ; Chanda P; Bader JS; McManus OB; Li M
Assay Drug Dev Technol; 2010 Dec; 8(6):743-54. PubMed ID: 21158688
[TBL] [Abstract][Full Text] [Related]
7. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride.
Zeng H; Penniman JR; Kinose F; Kim D; Trepakova ES; Malik MG; Dech SJ; Balasubramanian B; Salata JJ
Assay Drug Dev Technol; 2008 Apr; 6(2):235-41. PubMed ID: 18471077
[TBL] [Abstract][Full Text] [Related]
8. Cell-Based hERG Channel Inhibition Assay in High-Throughput Format.
Zhao J; Xia M
Methods Mol Biol; 2022; 2474():21-28. PubMed ID: 35294752
[TBL] [Abstract][Full Text] [Related]
9. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
10. Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach.
Piper DR; Duff SR; Eliason HC; Frazee WJ; Frey EA; Fuerstenau-Sharp M; Jachec C; Marks BD; Pollok BA; Shekhani MS; Thompson DV; Whitney P; Vogel KW; Hess SD
Assay Drug Dev Technol; 2008 Apr; 6(2):213-23. PubMed ID: 18471075
[TBL] [Abstract][Full Text] [Related]
11. Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels.
Su X; Young EW; Underkofler HA; Kamp TJ; January CT; Beebe DJ
J Biomol Screen; 2011 Jan; 16(1):101-11. PubMed ID: 21131594
[TBL] [Abstract][Full Text] [Related]
12. Observations on conducting whole-cell patch clamping of the hERG cardiac K
Kang J; Luo Y; Searles M; Rampe D
J Appl Toxicol; 2017 Apr; 37(4):445-453. PubMed ID: 27553911
[TBL] [Abstract][Full Text] [Related]
13. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
14. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
15. Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition.
Rast G; Guth BD
J Pharmacol Toxicol Methods; 2014; 70(2):182-7. PubMed ID: 25117629
[TBL] [Abstract][Full Text] [Related]
16. Halide ion effects on human Ether-à-go-go related gene potassium channel properties.
Zeng H; Balasubramanian B; Penniman JR; Kinose F; Salata JJ; Lagrutta A
Assay Drug Dev Technol; 2013; 11(9-10):544-50. PubMed ID: 24147984
[TBL] [Abstract][Full Text] [Related]
17. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
20. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
